TG Therapeutics is a commercial-stage biotech focused on a single approved product: BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody for relapsing forms of multiple sclerosis (RMS). BRIUMVI works by depleting CD20-positive B-cells that drive MS-related inflammation, and is administered as a one-hour IV infusion every 24 weeks. Its key selling point relative to the dominant competitor, Roche's Ocrevus, is a shorter infusion time and twice-yearly dosing schedule. TG sells BRIUMVI directly to neurologists, MS centers, and infusion centers across the U.S. and Canada/Mexico, and has out-licensed ex-U.S. rights to Neuraxpharm in exchange for milestone payments and tiered royalties. Revenue is driven by new patient starts, how long patients stay on therapy, and expansion into new prescribers — TG estimates it captures roughly 1 in 3 new IV anti-CD20 starts in the U.S. Manufacturing is fully outsourced to Samsung Biologics, keeping capital requirements lean, though TG pays royalties to LFB Group on net sales. TG has two key pipeline programs to extend BRIUMVI's reach: a Phase 3 trial evaluating a subcutaneous, self-administered formulation (data expected late 2026/early 2027, potential launch 2028), which management believes could nearly double its addressable market, and the ENHANCE trial testing a simplified single-visit starting regimen (data expected mid-2026). TG also has early-stage programs in progressive MS using an allogeneic CAR-T therapy and in myasthenia gravis.